Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study

We evaluated the impact of liposomal doxorubicin (NPLD) supercharge‐containing therapy on interim fluorodeoxyglucose positron emission tomography (interim‐FDG‐PET) responses in high‐risk diffuse large B‐cell lymphoma (DLBCL) or classical Hodgkin lymphoma (c‐HL). In this phase II study (2016–2021), 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Picardi, Marco, Giordano, Claudia, Pugliese, Novella, Esposito, Maria, Fatigati, Melania, Muriano, Francesco, Rascato, Maria G., Pepa, Roberta Della, D'Ambrosio, Alessandro, Vigliar, Elena, Troncone, Giancarlo, Russo, Daniela, Mascolo, Massimo, Esposito, Giovanni, Prastaro, Mariella, Esposito, Roberta, Tocchetti, Carlo G., Fonti, Rosa, Mainolfi, Ciro, Del Vecchio, Silvana, Pane, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541306/
https://www.ncbi.nlm.nih.gov/pubmed/35819919
http://dx.doi.org/10.1111/bjh.18348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541306/
https://www.ncbi.nlm.nih.gov/pubmed/35819919
http://dx.doi.org/10.1111/bjh.18348

Ejemplares similares